Global Rheumatoid Arthritis Therapeutics Market size is anticipated to exhibit 4.8% CAGR and reach valuation of US$ 33,958.8 Mn in 2025.
Major Players in the market contains AbbVie, Boehringer Ingelheim, Novartis, Regeneron Pharmaceuticals, Pfizer, Bristol-Myers Squibb, F. Hoffmann-La Roche, UCB S.A and Johnson & Johnson Services.
Oct 2020, AbbVie announced the presentation of new data on RINVOQ (upadacitinib) and HUMIRA across multiple rheumatic diseases at the American College of Rheumatology's annual meeting (ACR Convergence 2020), to be held virtually November 5-9. A total of 38 abstracts, including seven oral presentations, will be presented from a broad range of studies in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. "At AbbVie, we have a focused vision of improving the care and advancing treatment options for people living with rheumatic diseases, which is illustrated by the body of research that will be presented at this year's ACR meeting," said Marek Honczarenko M.D., Ph.D., vice president, global immunology development, AbbVie.
Nov 2020, Novartis announced 12-week results from the first-of-its-kind Phase IIIb ULTIMATE randomized controlled trial, which demonstrated the significant treatment response of Cosentyx (secukinumab) on synovitis (joint lining inflammation) in psoriatic arthritis (PsA) versus placebo. Synovitis was assessed using an advanced and sensitive imaging technique called Power Doppler ultrasonography (PDUS). These data are being presented at the American College of Rheumatology (ACR) All-Virtual Annual Meeting.
March 2020, the longtime developmental partners are aiming to see if Kevzara, a treatment for rheumatoid arthritis, could be effective against symptoms related to COVID-19. Regeneron Chief Scientific Officer George Yancopoulos told The Wall Street Journal if Kevzara could ease damage to the lungs and respiratory system caused by the body’s overreaction to COVID-19. Kevzara would not treat the underlying virus, just the immune system responses. Yancopoulos said the companies hope to have a trial “up and running” over the next several weeks or months in order to have data.
By product type it has Biologics, Non-Biologics, Non-Steroidal Anti-Inflammatory Drugs, Synthetic Disease-Modifying Antirheumatic Drugs. By distribution Channel it includes Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. By region it has ASPAC, North America, Europe and Row. North America is currently dominating the rheumatoid arthritis therapeutics market in the region. This is attributed due to such as growing prevalence of rheumatoid arthritis patients, strong clinical pipeline, favorable reimbursement policies, and high healthcare infrastructure. Moreover, rising healthcare spending and growing approval of novel drugs are some of the factors that are propelling the market growth. Asia Pacific is expected to witness tremendous growth over the forecast period. This is owing to rising healthcare spending and favorable regulatory policies for biosimilars in the region, that are major key factors contributing to the market growth.
.For more information contact @